Similarly, patients with obesity who were taking a reduced dose of the CYP3A4 substrate drug concomitantly with posaconazole should also observe the same washout period before resuming the recommended monotherapy maintenance dose. This evidence concerns the gene CYP3A4 and obesity disorder.